Literature DB >> 22354305

Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.

Maiken Cavling Arendrup1, David S Perlin, Rasmus Hare Jensen, Susan Julie Howard, Joanne Goodwin, William Hope.   

Abstract

We recently observed that the micafungin MICs for some Candida glabrata fks hot spot mutant isolates are less elevated than those for the other echinocandins, suggesting that the efficacy of micafungin may be differentially dependent on such mutations. Three clinical C. glabrata isolates with or without (S3) fks hot spot mutations R83 (Fks2p-S663F) and RR24 (Fks1p-S629P) and low, medium, and high echinocandin MICs, respectively, were evaluated to assess the in vivo efficacy in an immunocompetent mouse model using three doses of each echinocandin. Drug concentrations were determined in plasma and kidneys by high-performance liquid chromatography (HPLC). A pharmacokinetic-pharmacodynamic mathematical model was used to define the area under the concentration-time curve (AUC) that produced half- and near-maximal activity. Micafungin was equally efficacious against the S3 and R83 isolates. The estimates for the AUCs of each echinocandin that induced half-maximal effect (E(50)s) were 194.2 and 53.99 mg · h/liter, respectively. In contrast, the maximum effect (E(max)) for caspofungin was higher against S3 than R83, but the estimates for E(50) were similar (187.1 and 203.5 mg · h/liter, respectively). Anidulafungin failed to induce a ≥1-log reduction for any of the isolates (AUC range, 139 to 557 mg · h/liter). None of the echinocandins were efficacious in mice challenged with the RR24 isolate despite lower virulence (reduced maximal growth, prolonged lag phase, and lower kidney burden). The AUC associated with half-maximal effect was higher than the average human exposure for all drug-dose-bug combinations except micafungin and the R83 isolate. In conclusion, differences in micafungin MICs are associated with differential antifungal activities in the animal model. This study may have implications for clinical practice and echinocandin breakpoint determination, and further studies are warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22354305      PMCID: PMC3346593          DOI: 10.1128/AAC.06369-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

Review 1.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

2.  Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.

Authors:  Santosh Katiyar; Michael Pfaller; Thomas Edlind
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Authors:  S Park; R Kelly; J Nielsen Kahn; J Robles; M-J Hsu; E Register; W Li; V Vyas; H Fan; G Abruzzo; A Flattery; C Gill; G Chrebet; S A Parent; M Kurtz; H Teppler; C M Douglas; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.

Authors:  J Hiemenz; P Cagnoni; D Simpson; S Devine; N Chao; J Keirns; W Lau; D Facklam; D Buell
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.

Authors:  Susan J Howard; Joanne Livermore; Andrew Sharp; Joanne Goodwin; Lea Gregson; A Alastruey-Izquierdo; D S Perlin; Peter A Warn; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

6.  Five-hour diagnosis of dermatophyte nail infections with specific detection of Trichophyton rubrum.

Authors:  Anna Brillowska-Dabrowska; Ditte Marie Saunte; Maiken Cavling Arendrup
Journal:  J Clin Microbiol       Date:  2007-01-31       Impact factor: 5.948

7.  Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.

Authors:  Christopher D Miller; Ben W Lomaestro; Steven Park; David S Perlin
Journal:  Pharmacotherapy       Date:  2006-06       Impact factor: 4.705

8.  Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

Authors:  Julie A Stone; Sherry D Holland; Peter J Wickersham; Andrew Sterrett; Michael Schwartz; Cynthia Bonfiglio; Michael Hesney; Gregory A Winchell; Paul J Deutsch; Howard Greenberg; Thomas L Hunt; Scott A Waldman
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.

Authors:  Mikkel Krogh-Madsen; Maiken Cavling Arendrup; Lars Heslet; Jenny Dahl Knudsen
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

10.  Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

Authors:  Michel Laverdière; Richard G Lalonde; Jean-Guy Baril; Donald C Sheppard; Steven Park; David S Perlin
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790

View more
  50 in total

1.  Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.

Authors:  Rasmus Hare Jensen; Ulrik Stenz Justesen; Annika Rewes; David S Perlin; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.

Authors:  Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Laura Judith Marcos-Zambrano; Carlos Sánchez-Carrillo; Elia Gómez G de la Pedrosa; Rafael Cantón; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

3.  Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates.

Authors:  Mariana Castanheira; Leah N Woosley; Shawn A Messer; Daniel J Diekema; Ronald N Jones; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

4.  Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.

Authors:  Michael A Pfaller; Daniel J Diekema; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

Review 5.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 6.  Mechanisms of Antifungal Drug Resistance.

Authors:  Leah E Cowen; Dominique Sanglard; Susan J Howard; P David Rogers; David S Perlin
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

Review 7.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

8.  Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie Jaramillo; Marcos Olivo; Jason Pizzini; Gabriel Catano; Thomas F Patterson
Journal:  J Antimicrob Chemother       Date:  2018-02-01       Impact factor: 5.790

9.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

10.  Paradoxical antifungal activity and structural observations in biofilms formed by echinocandin-resistant Candida albicans clinical isolates.

Authors:  Carla J Walraven; Stella M Bernardo; Nathan P Wiederhold; Samuel A Lee
Journal:  Med Mycol       Date:  2013-12-22       Impact factor: 4.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.